** Shares of biotechnology company Immutep IMM.AX rise as much as 2.2% to A$0.348, their highest since Nov. 14
** Co has announced initiation of phase-3 trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC)
** Says trial will include over 150 clinical sites in over 25 countries
** Co expects to enrol the first patient in Q1 of CY2025.
** Stock has fallen 0.5% YTD, as of last close
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。